Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: Comparison with dynamic triple-phase multidetector CT imaging

Journal of Magnetic Resonance Imaging

Volumn 34, Issue 1, 2011, Pages 69-78

  Haradome, Hiroki ^a,b   Grazioli, Luigi ^a   Tinti, Rita ^a   Morone, Mario ^a   Motosugi, Utaroh ^c   Sano, Katsuhiro ^c   Ichikawa, Tomoaki ^c   Kwee, Thomas C ^d   Colagrande, Stefano ^e  

^a UNIVERSITY OF BRESCIA   (Italy)

^b KYORIN UNIVERSITY   (Japan)

^c UNIVERSITY OF YAMANASHI   (Japan)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e UNIVERSITY OF FLORENCE   (Italy)

Author keywords

gadoxetic acid disodium; hepatocellular carcinoma; liver; MDCT; MRI

Indexed keywords

GADOXETIC ACID; IOPROMIDE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DYNAMIC MAGNETIC RESONANCE IMAGING; FALSE NEGATIVE RESULT; FEMALE; HEPATOBILIARY RADIOGRAPHY; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LIVER PARENCHYMA; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RADIOLOGY; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79959580240     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.22588     Document Type: Article

References (27)

1. Parkin DM, Bary F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. (Pubitemid 40372904)
2. American Cancer Society. Cancer facts and figures 2005. Atlanta, GA: American Cancer Society; 2005.
3. Llovet JM, Brà C, Bruix J,. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338.
4. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 14: 693-699. (Pubitemid 26079803)
5. Freeman RB, Mithoefer A, Ruthazer R, et al. Optimizing staging for hepatocellular carcinoma before liver transplantation: a retrospective analysis of the UNOS/OPTN data base. Liver Transpl 2006; 12: 1504-1511. (Pubitemid 44594281)
6. Peterson MS, Baron RL, Marsh JW Jr, Oliver JH, 3rd, Confer SR, Hunt LE,. Pretransplantation surveillance for possible hepatocellular carcinoma in patients with cirrhosis: epidemiology and CT-based tumor detection rate in 430 cases with surgical pathologic correlation. Radiology 2000; 217: 743-749.
7. Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of non-invasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008; 47: 97-104. (Pubitemid 351171046)
8. Reimer P, Schneider G, Schima W,. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol 2004; 14: 559-578. (Pubitemid 38444568)
9. Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT-initial observations. Radiology 2004; 230: 266-275. (Pubitemid 37549812)
10. Huppertz A, Balzer T, Blakeborough A, et al. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 2004; 230: 266-275. (Pubitemid 37549812)
11. Bruix J, Sherman M,. Practical Guidelines Committee, American Association for the Study of Liver Disease management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
12. Bruix J, Sherman M, Llovet JM, et al. EASL Panel Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001; 35: 421-430. (Pubitemid 32844200)
13. Kim SH, Kim SH, Lee J, et al. Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 2009; 192: 1675-1681.
14. Di Martino M, Marin D, Guerrisi A, et al. Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis. Radiology 2010; 256: 806-816.
15. Akai H, Kiryu S, Matsuda I, et al. Detection of hepatocellular carcinoma by Gd-EOB-DTPA-enhanced liver MRI: comparison with triple phase 64 detector row helical CT. Eur J Radiol 2010 DOI:10.1016/j.ejrad.2010.07.026.
16. Ahn SS, Kim MJ, Lim JS, et al. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 2010; 255: 459-466.
17. Mita K, Kim SR, Kudo M, et al. Diagnostic sensitivity of imaging modalities for hepatocellular carcinoma smaller than 2 cm. World J Gastroenterol 2010; 16: 4187-4192.
18. Ichikawa T, Saito K, Yoshioka N, et al. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol 2010; 45: 133-141.
19. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. IAMA 2000; 284: 3043-3045.
20. Haradome H, Grazioli L, Tsunoo M, et al. Can MR fluoroscopic triggering technique and slow rate injection provide appropriate arterial phase images with reducing artifacts on gadoxetic acid-DTPA (Gd-EOB-DTPA)-enhanced hepatic MR imaging? J Magn Reson Imaging 2010; 32: 334-340.
21. Frericks BB, Loddenkemper C, Huppertz A, et al. Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA. AJR Am J Roentgenol 2009; 193: 1053-1060.
22. Vogl TJ, Kummel S, Hammerstingl R, et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 1996; 200: 59-67. (Pubitemid 26197732)
23. Rofsky NM, Lee VS, Laub G, et al. Abdominal MR imaging with a volumetric interpolated breath-hold examination. Radiology 1999; 212: 876-884. (Pubitemid 29410996)
24. Zhao H, Yao JL, Wang Y, Zhou KR,. Detection of small hepatocellular carcinoma: comparison of dynamic enhancement magnetic resonance imaging and multiphase multirow-detector helical CT scanning. World J Gastroenterol 2007; 13: 1252-1256. (Pubitemid 46592970)
25. Cruite I, Schroeder M, Merkle EM, Sirlin CB,. Gadoxetate disodium-enhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic liver. AJR Am J Roentgenol 2010; 195: 29-41.
26. Doo KW, Lee CH, Choi JW, et al. "Pseudo washout" sign in high-flow hepatic hemangioma on gadoxetic acid contrast-enhanced MRI mimicking hypervascular tumor. AJR Am J Roentgenol 2009; 193: W490-496.
27. Motosugi U, Ichikawa T, Sou H, et al. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. Radiology 2010; 256: 151-158.